CARDINAL HEALTH COLLABORATES WITH TRAKCEL TO STREAMLINE CELL AND GENE THERAPY COMMERCIALIZATION

Cardinal Health announced a new agreement with TrakCel to offer an integrated cell and gene therapy (CGT) software solution to help biopharma companies track autologous cell therapies through multiple stages of development and commercialization.

 
Autologous cell therapies are personalized medicines, created by removing a patient’s own cells, processing them outside the body, and reintroducing them to the patient. Because they hold the promise of significant new therapeutic potential for many diseases that traditional medicines do not cure, they are generating great interest, and exponential growth is projected in this market: The current U.S. CGT market size is currently valued at $5 billion, and is projected to grow to $25.7 billion by 2027, according to 2023 Evaluate Pharma data.

“Bringing a CGT product to market is immensely complex for developers,” said Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, which includes the Advanced Therapy Solutions business. “Some of the greatest challenges are in manufacturing, regulatory approval, logistics and reimbursement. And that’s where our new collaboration with TrakCel comes in: It brings visibility and tracking capabilities to manufacturers, allowing them to track the chain of identity and chain of custody to ensure patient safety. Ultimately, our collaboration helps CGT developers accelerate speed to market and get these therapies to patients more quickly.”

The CGT sector has some of the most complex supply chains in healthcare. Advanced Therapy Solutions will work with TrakCel to simplify the challenges: Shared customers can take advantage of Cardinal Health’s Sonexus™ Access and Patient Support hub platform and 3PL order-to-cash and distribution capabilities plus OCELLOS, TrakCel’s second-generation advanced therapy orchestration platform for cell and gene therapy manufacturers.